Addex Therapeutics Ltd

XMUN:APE

Business Description

Sector

Health Care

Industry

Pharmaceuticals

Headquarters

Switzerland CH

Employees

3

IPO date

May 22, 2007

Addex Therapeutics is a drug development company focused on medicines that act on G protein-coupled receptors, especially through a method called allosteric modulation. In plain English, it tries to make small-molecule drugs that fine-tune how receptors in the brain and body work, rather than simply switching them on or off. Its main work is centered on treatments for nervous system and inflammatory diseases, where receptor control can affect symptoms and disease pathways.

The company does not sell a broad line of finished medicines. Instead, it earns value by advancing research programs, partnering with larger pharmaceutical companies, and licensing out drug candidates or technology rights when it can. Its customers and counterparties are mainly drug makers, research partners, and, eventually, patients and doctors if a program becomes an approved therapy. Like many biotech firms, its business model depends on building proprietary drug assets and sharing in the value if those assets move through development.

What makes Addex different is its focus on allosteric drugs, a niche approach that can offer more precise control than traditional receptor-targeting medicines. That places the company in the early-stage drug discovery part of the pharmaceutical value chain, where scientific know-how and patentable programs matter more than manufacturing or sales scale. The business is therefore driven by research milestones, partnerships, and the long path from laboratory discovery to potential clinical products.